retatrutide peptide trial Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide Triple Agonist Research |

December 15, 2021

Some state Medicaid programs cover both diabetes and weight management indications

GLP-1-driven demand for high-protein whey has created its own market dynamics, increasingly independent of commodity whey pricing, and if your contracts still index high-protein products to commodity whey, thats a 2026 risk worth auditing before renewal

If something feels offmore tired than expected, a little shaky, not quite rightits worth noticing instead of pushing through

They are like nonergot DAs in that they help with dyskinesia and motor fluctuations, but their use is limited due to cardiac side effects, including fibrosis and restrictive heart valve changes